Synthetic peptide as treatment for down's syndrome and schizophrenia
OwnerBinie V. Lipps, Frederick W. Lippsinventors
Life of this patent
Estimating the term…
Abstract
Adesh is a synthetic peptide consisting of at least the first four amino acids from the N-terminal of the sequence N L G E H P V C D S T D T W V (SEQ. ID. NO.: 1) and no more than 25 amino acids total. The synthetic peptide mimics the biological properties of nerve growth factor (NGF) consisting of 116 amino acids and is advocated to treat Down Syndrome (DS) and schizophrenia. It is believed that these neuro-degenerative diseases are linked with inadequate neurotrophic factors.
Claims17
The invention discovered that individuals having Down syndrome show low level of nerve growth factor (NGF).
Synthetic Adesh consisting of SEQ. ID. NO.:
- 2 is advocated as a treatment for neurological disorders;
- Down syndrome and schizophrenia.
Composition of synthetic Adesh as a treatment for people who are diagnosed for Down syndrome and schizophrenia. Adesh treatment increases the NGF level which improves the physical and cognitive symptoms in DS victims.
The composition of synthetic Adesh as set forth in SEQ. I.D. NO.:
- 2.
A method for treating a condition selected from the group consisting of Down's Syndrome and Schizophrenia in humans, comprising
- identifying a patient suffering from one of said conditions, and
- administering a peptide to said patient;
- wherein the peptide comprises at least the first four amino acids from the N-terminal of SEQ. ID. NO.:
- 1 and no more than 25 amino acids total.
Dependencies are inferred from the claim text.